Preparation and standardization of U.S. Standard Pertussis Vaccine, Lot No. 11.
The Center for Biologics Evaluation and Research within the U.S. Food and Drug Administration has prepared a new U.S. Standard Pertussis Vaccine. Whole cell pertussis vaccine concentrate was diluted in 5% (w/v) lactose and lyophilized. The preparation was tested for toxicity, sterility, heterogeneity and residual moisture. Based on data from an international collaborative study involving 11 laboratories, the potency was estimated in relation to the U.S. Master Standard Pertussis Vaccine, Lot 4 and the International Standard for Pertussis Vaccine, Lot 2. The potency of the preparation was defined to be 90 units per ampoule. When reconstituted and stored according to instructions, no significant change in potency was observed in the 14 days following reconstitution. This material was shown to be suitable for a pertussis vaccine standard and accordingly it was designated as U.S. Standard Pertussis Vaccine, Lot 11 on March 22, 1994.
Jansen
D L
DL
Food and Drug Administration, Rockville, MD 20852-1448, USA.
Meade
B D
BD
D000818:Animals; D001681:Biological Assay; D055598:Chemical Phenomena; D002627:Chemistry, Physical; D005612:Freeze Drying; D006801:Humans; D051379:Mice; D008875:Middle Aged; D010567:Pertussis Vaccine / Q000302:isolation & purification / Q000592:standards*; D011309:Preservation, Biological; D012015:Reference Standards; D015203:Reproducibility of Results; D014481:United States
D010567:Pertussis Vaccine